Guiselin Thomas, Lecoutey Cédric, Rochais Christophe, Dallemagne Patrick
Normandie University, Unicaen, Centre d'Etudes et de Recherche sur le Médicament de Normandie (CERMN), 14000 Caen, France.
Pharmaceutics. 2023 Sep 26;15(10):2382. doi: 10.3390/pharmaceutics15102382.
The multifactorial nature of some diseases, particularly neurodegenerative diseases such as Alzheimer's disease, frequently requires the use of several drugs. These drug cocktails are not without drawbacks in terms of increased adverse effects, drug-drug interactions or low adherence to treatment. The use of pleiotropic drugs, which combine, within a single molecule, several activities directed against distinct therapeutic targets, makes it possible to overcome some of these problems. In addition, these pleiotropic drugs generally lead to the expression of a synergy of effects, sometimes greater than that observed with a combination of drugs. This article will review, through recent examples, the different kinds of pleiotropic drugs being studied or already present on the market of medicines, with a focus on the structural aspect of such drug design.
某些疾病,尤其是神经退行性疾病如阿尔茨海默病,具有多因素性质,常常需要使用多种药物。这些药物组合在增加不良反应、药物相互作用或治疗依从性低方面并非没有缺点。使用多效性药物,即在单个分子内结合针对不同治疗靶点的多种活性,有可能克服其中一些问题。此外,这些多效性药物通常会导致效应协同作用的表达,有时比药物组合所观察到的协同作用更大。本文将通过最近的实例,综述正在研究或已在药品市场上出现的不同种类的多效性药物,重点关注此类药物设计的结构方面。